NAS:STML (USA) Also trade in: Germany

Stemline Therapeutics Inc

$ 14.3 0 (0%)
Volume: 613,463 Avg Vol (1m): 616,225
Market Cap $: 624.69 Mil Enterprise Value $: 500.33 Mil
P/E (TTM): 0.00 P/B: 4.94
Earnings Power Value -7.15
Net Current Asset Value 2.84
Tangible Book 2.9
Projected FCF -7.73
Median P/S Value 99.16
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
79.50% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
STML: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.01, Med: 10000, Max: 10000
Current: 10000
1.01
10000
Equity-to-Asset 0.80
Equity-to-Asset ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
STML: 0.8
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.8, Med: 0.92, Max: 0.96
Current: 0.8
0.8
0.96
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.44
DISTRESS
GREY
SAFE
Beneish M-Score 10.95
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 9.12%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1893.15
Operating Margin ranked lower than
91.04% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
STML: -1893.15
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -33773.24, Med: -8653.73, Max: -1893.15
Current: -1893.15
-33773.24
-1893.15
Net Margin % -1862.05
Net Margin ranked lower than
91.04% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
STML: -1862.05
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -34080.28, Med: -8605.97, Max: -1862.05
Current: -1862.05
-34080.28
-1862.05
ROE % -122.41
ROE ranked lower than
73.31% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
STML: -122.41
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -1800.57, Med: -60.84, Max: 173.12
Current: -122.41
-1800.57
173.12
ROA % -96.32
ROA ranked lower than
78.32% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
STML: -96.32
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -130.3, Med: -46.93, Max: -24
Current: -96.32
-130.3
-24
ROC (Joel Greenblatt) % -48045.22
ROC (Joel Greenblatt) ranked lower than
96.04% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
STML: -48045.22
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -84785, Med: -35227.43, Max: -9458.4
Current: -48045.22
-84785
-9458.4
3-Year Total Revenue Growth Rate -100.00
3-Year Revenue Growth Rate ranked higher than
70.66% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
STML: -100
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -50, Max: -100
Current: -100
0
-100
3-Year Total EBITDA Growth Rate -31.40
3-Year EBITDA Growth Rate ranked lower than
65.59% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
STML: -11.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -68.3, Med: -23.1, Max: 2.1
Current: -11.3
-68.3
2.1
3-Year EPS w/o NRI Growth Rate -11.60
3-Year EPS w/o NRI Growth Rate ranked lower than
65.01% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
STML: -11.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» STML's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:STML

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare OSTO:ONCO NAS:MGTX XKRX:263050 NAS:OSIR OTCPK:PRED OCSE:ZEAL ROCO:4105 NAS:DTIL NAS:TGTX SHSE:603566 SZSE:300653 NAS:LXRX NAS:CRNX NAS:DERM NAS:ARQL OCSE:BAVA TSE:2931 LSE:OXB NAS:ATNX SZSE:300497
Traded in other countries S46.Germany
Address 750 Lexington Avenue, 11th Floor, New York, NY, USA, 10022
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. It is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. It is developing clinical stage product candidates namely SL-401, SL-801, and SL-701. The company is also involved in advancing its clinical stage programs, expanding and strengthening its intellectual property portfolio, identifying and acquiring additional product and technology rights.

Ratios

Current vs industry vs history
PB Ratio 4.94
PB Ratio ranked lower than
57.28% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
STML: 4.94
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.87, Med: 3.01, Max: 10.56
Current: 4.94
0.87
10.56
PS Ratio 106.71
PS Ratio ranked lower than
93.94% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
STML: 106.71
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 84.1, Med: 740, Max: 13500
Current: 106.71
84.1
13500
EV-to-EBIT -5.29
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
STML: -5.29
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -14.4, Med: -4.2, Max: -0.7
Current: -5.29
-14.4
-0.7
EV-to-EBITDA -5.29
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
STML: -5.29
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -14.4, Med: -4.2, Max: -0.7
Current: -5.29
-14.4
-0.7
EV-to-Revenue 99.09
EV-to-Revenue ranked lower than
90.27% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
STML: 99.09
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -99999999.99, Med: 545.1, Max: 4826.2
Current: 99.09
-99999999.99
4826.2
Current Ratio 5.07
Current Ratio ranked higher than
55.49% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
STML: 5.07
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.42, Med: 5.38, Max: 31.09
Current: 5.07
0.42
31.09
Quick Ratio 5.03
Quick Ratio ranked higher than
57.36% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
STML: 5.03
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.42, Med: 5.38, Max: 31.09
Current: 5.03
0.42
31.09
Days Inventory 719.81
Days Inventory ranked lower than
100.00% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
STML: 719.81
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 0, Med: 0, Max: 719.81
Current: 719.81
0
719.81
Days Sales Outstanding 406.21
Days Sales Outstanding ranked higher than
53.44% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
STML: 406.21
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 166.87, Med: 535.06, Max: 903.24
Current: 406.21
166.87
903.24

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.90
3-Year Share Buyback Rate ranked lower than
66.98% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
STML: -15.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -56.9, Med: -30.95, Max: -13.6
Current: -15.9
-56.9
-13.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.93
Price-to-Tangible-Book ranked higher than
51.45% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
STML: 4.93
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.1, Med: 3.22, Max: 8.39
Current: 4.93
1.1
8.39
Price-to-Median-PS-Value 0.14
Price-to-Median-PS-Value ranked lower than
74.93% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
STML: 0.14
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.13, Med: 0.76, Max: 14.46
Current: 0.14
0.13
14.46
Earnings Yield (Joel Greenblatt) % -18.90
Earnings Yield (Greenblatt) ranked lower than
70.31% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
STML: -18.9
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -135.7, Med: -23.8, Max: -6.9
Current: -18.9
-135.7
-6.9

More Statistics

Revenue (TTM) (Mil) $ 5.05
EPS (TTM) $ -3.04
Beta 1.12
Volatility % 52.41
52-Week Range $ 7.82 - 20.55
Shares Outstanding (Mil) 43.68

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y